Search clinical trials for: Quetiapine(Seroquel-XR) 50~800mg a day

Total 104 results

Severance Hospital

Unknown

Effects of 'Seroquel-XR' on the Improvement of Neurocognitive Function in People At-risk Mental States(ARMS) (ES-ARMS)

Schizophrenia | Abnormal Mental State

Korea, Republic of
University of North Carolina, Chapel Hill
AstraZeneca

Completed

Open Label Seroquel (Quetiapine) Study for Treatment Resistant Functional Bowel Disorder

Functional Bowel Disorders

United States
University Hospitals Cleveland Medical Center
National Alliance for Research on Schizophrenia and Depression; AstraZeneca

Completed

Quetiapine Extended Release (XR) in Bipolar Patients With Comorbid Generalized Anxiety Disorder (GAD)

Anxiety Disorders | Anxiety | Bipolar Disorder | Substance Use Disorders

United States
Otsuka Pharmaceutical Development & Commercialization...
PRA Health Sciences

Completed

Trial to Assess the Bioavailability of Quetiapine Versus Seroquel® in Subjects With Schizophrenia or Bipolar Disorder

Schizophrenia | Bipolar Disorder

United States
AstraZeneca

Completed

Efficacy and Safety of SEROQUEL Extended Release (XR) in Acute Schizophrenia

Schizophrenia

Malaysia
AstraZeneca

Completed

Compare the Effect on Cognitive Functioning of Two Formulations of Seroquel, Seroquel XR and IR in Patients With Stable Schizophrenia (eXtRa)

Schizophrenia

Italy, Germany, Austria, Spain, Denmark
Inje University

Unknown

The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope

Major Depressive Disorder

Korea, Republic of
Indiana University School of Medicine
AstraZeneca

Completed

Brain Imaging of Quetiapine Response in Anxious Depression

Major Depression

United States
BC Women's Hospital & Health Centre

Completed

Quetiapine in the Treatment of Postpartum Depression (PPD) in Bipolar Disorder (BD), Type II

Postpartum Depression

Canada
Sunnybrook Health Sciences Centre
AstraZeneca

Completed

Identifying Very Early Response to Seroquel Extended Release (XR) Augmentation for Major Depressive Disorder

Depressive Disorder, Major

Canada
AstraZeneca

Terminated

Study of the Broad Clinical Benefit for Seroquel XR With Flexible Dose as an add-on Therapy in the Treatment of Acute Bipolar Mania Patients With Partial Response to Current Therapy (RELEASE)

Acute Bipolar Mania

Korea, Republic of
Indiana University
AstraZeneca

Completed

A Study of Quetiapine SR (Seroquel SR) to Treat SSRI-Resistant, Comorbid Panic Disorder Patients

Panic Disorder

United States
H. Lundbeck A/S

Completed

Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder

Schizophrenia | Schizoaffective Disorder

United States
AstraZeneca

Completed

Study Comparing the Tolerability of Seroquel IR With Seroquel XR in Patients With Bipolar Depression

Bipolar Depression
Bayside Health
AstraZeneca

Unknown

Quetiapine Extended Release (XR) for the Management of Psychotic Aggression or Agitation in Adult Acute Psychiatry

Schizophrenia | Psychosis

Australia
Sumitomo Pharma America, Inc.

Completed

A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.

Schizophrenia

United States, Romania, Russian Federation, Ukraine
Emory University
Duke University; University of Toronto

Terminated

Quetiapine XR for Cognitive and Functional Disability in Clinically Stable Patients With Bipolar Disorder

Cognitive Impairment | Bipolar Disorder

United States
AstraZeneca

Terminated

Seroquel XR in Adults With Schizophrenia

Schizophrenia

Thailand
AstraZeneca

Completed

Study of the Efficacy and Safety of Quetiapine Fumarate Extended Release (Seroquel XR) (QUENCH)

Schizophrenia

Korea, Republic of
University Hospital Muenster
AstraZeneca

Completed

Quetiapine in Specific Phobia (QUISS)

Specific Phobia

Germany
Duke University

Terminated

An Open Label, Double-blind Discontinuation Study of Quetiapine Extended Release(XR)

Social Anxiety Disorder

United States
AstraZeneca

Completed

Pediatric Bipolar Depression

Bipolar Depression

United States, Mexico, Taiwan, South Africa, Serbia, India, Colombia
AstraZeneca

Completed

Generalized Anxiety Disorder Adjunct Study

Anxiety Disorders | Anxiety | Anxiety Neuroses | Anxiety States

United States
AstraZeneca
Quintiles, Inc.

Completed

Adult Bipolar Mania

Acute Mania

Bulgaria, Poland, Russian Federation, South Africa, Germany, Ukraine, Israel, India, Belgium
Galapagos NV

Completed

Single and Multiple Dose Pharmacokinetics of GLPG0634 in Elderly Healthy Subjects

Healthy

Belgium
Subhajit Chakravorty

Completed

The Effects of Quetiapine (Seroquel XR) on Sleep During Alcohol Abstinence

Alcoholism | Sleep Initiation and Maintenance Disorders

United States
Icahn School of Medicine at Mount Sinai
AstraZeneca

Completed

Efficacy of Extended-release Quetiapine (Seroquel XR) as Adjunctive Therapy to Cognitive Behavioral Therapy in the Treat

Generalized Anxiety Disorder | Major Depressive Disorder

United States
Astellas Pharma Inc

Completed

Study to Evaluate the Effect and Safety of Quetiapine Extended Release (XR) (FK949E) in Major Depressive Disorder

Major Depressive Disorder

Japan
University of Calgary
AstraZeneca

Completed

Serotonin Transporter Genetic Variation and Amygdala Responses to Antidepressant Medications in Major Depression

Major Depressive Disorder

Canada
Weill Medical College of Cornell University
AstraZeneca

Terminated

Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines

Generalized Anxiety Disorder | Major Depression

United States
Hospital de Clinicas de Porto Alegre

Unknown

Brain Derived Neurotrophic Factor as a Predictor of Response to Treatment in Bipolar Depression and Mania: 16-weeks Follow-up With Quetiapine XR

BIPOLAR DISORDER

Brazil
Loyola University

Completed

Cardiovascular Biomarkers and Quetiapine in Depression and Anxiety Patients

Depression | Anxiety

United States
McMaster University

Completed

Quetiapine Extended Release (XR) for the Treatment of Menopausal Depression

Insomnia | Hot Flashes | Major Depressive Disorder

Canada
Keming Gao
AstraZeneca

Terminated

Quetiapine Extended Release (XR) Treatment of Major Depressive Disorder With Comorbid Generalized Anxiety Disorder (MDD/GAD)

Generalized Anxiety Disorder | Major Depressive Disorder

United States
Université de Sherbrooke
Université de Montréal

Completed

Quetiapine (Seroquel XR) for the Treatment of Fibromyalgia: a Clinical and Mechanistic Pilot Study

Fibromyalgia

Canada
Janssen-Cilag International NV

Completed

A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder (ESCAPE-TRD)

Depressive Disorder, Major

Israel, Hungary, Korea, Republic of, Taiwan, Portugal, Turkey, Germany, Malaysia, Denmark, Bulgaria, Czechia, Belgium, Poland, Brazil, Netherlands, Argentina, Finland, Greece, South Africa, Austria, Kazakhstan, Norway, Sweden, United...
University of Minnesota
AstraZeneca; University of Iowa; Mclean Hospital

Completed

Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD)

Borderline Personality Disorder

United States
Dr Alexander McIntyre Inc.

Completed

A Study of Quetiapine Fumarate Sustained Release in Major Depression With Comorbid Fibromyalgia Syndrome

Major Depression

Canada
AstraZeneca

Completed

Evaluate the Pharmacokinetics of Quetiapine Fumarate in Chinese Schizophrenic Patients

Schizophrenia

China
AstraZeneca

Completed

Positron Emission Tomography (PET) Study With [11C]Raclopride to Determine Central D2 Dopamine Occupancy of SEROQUEL (PET)

Depression

Sweden
National Institute on Alcohol Abuse and Alcoholism...
National Institute on Drug Abuse (NIDA); AstraZeneca; US Department of Veterans...

Completed

Study of the Effectiveness of Quetiapine for the Treatment of Alcohol Dependency

Alcoholism | Alcohol Abuse

United States
University of Calgary
Multiple Sclerosis Society of Canada

Completed

Safety and Tolerability of Quetiapine in Multiple Sclerosis

Multiple Sclerosis

Canada
Dr. D McIntosh & Dr. K Kjernisted Clinical Research...
AstraZeneca

Completed

Bipolar Study of Seroquel XR With Pramipexole Dihydrochloride

Bipolar Depression

United States, Canada
AstraZeneca

Terminated

Schizophrenic Patients in Integrated Care (CARE II)

Schizophrenia | Schizoaffective Disorder | Schizophreniform Disorder

Germany
Flinders University

Completed

Effects of Quetiapine on Sleep and Next Day Alertness in People With Obstructive Sleep Apnea (QOSA)

Sleep Apnea, Obstructive

Australia
AstraZeneca

Completed

Study Evaluating the Clinical Benefit of SEROQUEL XR in Subjects With Schizophrenia (SPECTRUM)

Schizophrenia

Canada, Australia, Korea, Republic of, Hong Kong
Mclean Hospital

Terminated

Generalized Anxiety and Seroquel (GAD)

Generalized Anxiety Disorder | Seroquel XR

United States
Bo-Hyun Yoon

Withdrawn

Efficacy of Quetiapine XR Versus Divalproex on Clinical Outcome Quality of Sleep and Quality of Life in Bipolar Depression

Bipolar Depression

Korea, Republic of
AstraZeneca

Completed

Quetiapine Fumarate Immediate Release (IR) Versus Extended Release (XR) Dose Escalation Comparison

Healthy Volunteers

United States
Seattle Institute for Biomedical and Clinical Research
AstraZeneca; VA Puget Sound Health Care System

Completed

Quetiapine for the Reduction of Cocaine Use (AZC)

Substance Abuse | Cocaine Dependence | Drug Abuse | Cocaine Abuse | Cocaine Addiction

United States

Search clinical trials for: Quetiapine(Seroquel-XR) 50~800mg a day

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cambodia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations